NurExone Biologic Inc. Announces Sublicense Agreement for U.S. Manufacturing
On March 26, 2026, NurExone Biologic Inc., a biotechnology company developing exosome-based therapies, announced that its subsidiaries Exo-Top Inc. and NurExone Biologic Ltd. entered into a sublicense agreement granting Exo-Top certain rights under an existing license. According to GlobeNewswire PE, the agreement stems from an exclusive worldwide development and commercialization license that NurExone originally signed with Technion Research and Development Foundation Ltd. and Ramot on June 23, 2020, which was later amended.
Agreement Details
Under the sublicense, Exo-Top Inc., a wholly owned U.S. subsidiary of NurExone, received rights to support manufacturing, development, and commercial activities for naïve exosomes in the U.S. The Company stated that this sublicense is intended to enhance strategic flexibility in the U.S. market and aligns with plans for North American operations. No monetary consideration was exchanged between Exo-Top and NurExone Ltd. for the sublicense, and as a result, no sublicense fees are expected to be payable to Technion Research and Development Foundation Ltd.
Strategic Role of Exo-Top
Exo-Top is positioned as a strategic U.S. subsidiary focused on supporting NurExone’s manufacturing, clinical advancement, and long-term value creation in exosome-based therapeutics. One of Exo-Top’s key assets is its Master Cell Bank, which ensures batch-to-batch consistency and serves as a reproducible starting point for manufacturing exosome therapies. Widely known in biotechnology, exosomes are extracellular vesicles used for regenerative medicine, and this agreement underscores Exo-Top’s role in maintaining quality and repeatability essential for clinical translation and commercial readiness.
Company Background and Statements
NurExone Biologic Inc., listed on the TSX Venture Exchange as NRX, OTCQB as NRXBF, and Frankfurt as J90, develops therapies for central nervous system injuries, with its lead product being ExoPTEN. Dr. Lior Shaltiel, Chief Executive Officer of NurExone, stated that the sublicense represents an important step in building Exo-Top as part of the company’s long-term U.S. strategy by aligning corporate structure with future manufacturing and commercialization plans. According to GlobeNewswire PE, the original Tech License requires NurExone to pay certain royalty fees to Technion Research and Development Foundation Ltd. upon reaching Phase II of clinical trials and on commercialization, though this sublicense does not trigger immediate payments. According to GlobeNewswire PE, this structure supports the company’s broader efforts in exosome bioproduction.
